39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2019 at "CNS Spectrums"
DOI: 10.1017/s1092852919000324
Abstract: Abstract Objective To evaluate the long-term safety and tolerability of once-dailyvalbenazine in adults with tardive dyskinesia(TD). Methods Data were pooled from KINECT 3 (NCT02274558: 6-week double-blind placebo-controlled period, followed by a 42-week double-blind extension and… read more here.
Keywords: valbenazine; study; long term; week ... See more keywords
Long-Term Effects of Once-Daily Valbenazine in Older and Younger Adults with Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000335
Abstract: Abstract Introduction Older patients taking a dopamine receptor blocking agent (eg, first- or second-generation antipsychotic) have an increased risk for tardive dyskinesia (TD), a persistent and potentially disabling movement disorder. Valbenazine, a selective and potent… read more here.
Keywords: valbenazine; long term; tardive dyskinesia; cgi pgic ... See more keywords
A Model-Informed Drug Development Approach Supporting the Approval of a New Valbenazine Dose for Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000402
Abstract: Abstract Introduction Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with dopamine receptor blocking agents (eg, antipsychotics). Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor with several safe and… read more here.
Keywords: tardive dyskinesia; development; model; aims cfb ... See more keywords
Sustained Treatment Response With Long-Term Valbenazine in Patients With Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2023 at "CNS Spectrums"
DOI: 10.1017/s1092852923001712
Abstract: Abstract Background Valbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics, antiemetics, and other dopamine receptor blocking… read more here.
Keywords: tardive dyskinesia; valbenazine; score; week ... See more keywords